ExodusPoint Capital Management, LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
ExodusPoint Capital Management, LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$48
-99.8%
32,143
+164.7%
0.00%
Q4 2021$30,000
-96.2%
12,142
-96.4%
0.00%
-100.0%
Q1 2021$785,000
-44.8%
334,197
-58.6%
0.01%
-21.4%
Q4 2020$1,421,000
+9373.3%
807,612
+5104.7%
0.01%
Q3 2020$15,000
+25.0%
15,517
+17.3%
0.00%
Q2 2020$12,00013,2240.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders